Although Helicobacter pylori (H. pylori) eradication has been shown to inhibit gastric cancer, it does not completely suppress it.
Dr Masaaki Kodama and colleagues from Japan examined risk factors of gastric cancer development following H. pylori eradication.
A total of 2355 patients underwent successful eradication of H. pylori.
Endoscopic atrophy, histological gastritis, atrophy, intestinal metaplasia (IM), and operative link for gastritis assessment (OLGA) staging were subsequently evaluated.
Following eradication, the team noted that 33 out of 2355 patients developed gastric cancer.
|The highest odds ratio for IM was at the greater curvature of the corpus|
|Scandanavian Journal of Gastroenterology|
Compared to a nongastric cancer group that was matched according to gender and age, the incidence of endoscopic atrophy, histological atrophy at the greater curvature of the antrum, inflammation, IM at the greater curvature of the corpus, the ratio of OLGA-stage 0–II/III, IV were significantly higher for the gastric cancer group.
The research team showed the highest odds ratio for IM at the greater curvature of the corpus.
Dr Kodama's team commented, "Severe endoscopical atrophy, OLGA staging, histological atrophy at the antrum, inflammation, and particularly IM at the corpus, were identified as risk factors for gastric cancer development following H. pylori eradication."
"Therefore, eradication should be performed before these predictors develop."